We are harnessing a unique type of stem cells to create novel classes of regenerative biotherapeutics, and deliver their benefit to patients.
Unicyte is the evolution of a research collaboration, begun in 2003, between the Camussi lab at the University of Turin and Fresenius Medical Care AG & Co. KGaA. We have translated the ground-breaking discoveries of that collaboration into a broad pipeline based on three major technology platforms.
We are now dedicated to translating this pipeline into therapies that will improve the lives of patients with kidney or liver disease, diabetes, and cancer.
HUMAN LIVER STEM CELLS
HUMAN LIVER STEM CELLS
HLSCs are unique adult stem cells capable not only of differentiation into multiple different cell types, but also of extensive self-renewal. They exhibit extremely high clonal stability, overcoming a major manufacturing limitation of many other stem cell sources – all while maintaining their high levels of regenerative potential in the liver and beyond.
We have received Orphan Drug Designation (from the European Medicines Agency) for HLSCs in several urea cycle disorders, and acute liver failure.
nEVs, membrane surrounded structures between 20 and 200nm in diameter are shed by many cell types, including our HLSCs. With a unique ability to transport cargo — including DNA, RNA, and proteins — between cells, nEVs play a fundamental biological role in the regulation of normal physiological processes. Following an explosion of high-profile publications on nEVs, these circulating vesicles are emerging as one of the most exciting avenues to both new therapies and diagnostics.
We have established a range of programmes based on our HLSC-nEV platform, and are moving this novel class of therapeutics towards the clinic for the safe and efficient treatment of liver & kidney disorders including transplantation, and cancer.
We have developed a one-step process leading from HLSCs to organoids resembling natural islets (HLSC-Islets) for the application in Type 1 diabetes mellitus. Through this process, the HLSCs differentiate into multi-hormonal islet like structures with more than >50% beta-cells expressing insulin. These structures, when implanted in diabetic animals, rapidly restore a normo-glycemic profile and display near-to-normal glycemia levels under IPGTT.
Based on the very positive preclinical efficacy, we are moving the HLSC-Islets through a preclinical programme towards the clinic.
While a fully owned subsidiary of Fresenius Medical Care, Unicyte is structured to facilitate various types of investments. We are open to a wide variety of models, be they broad or narrow, financial or technical, or therapeutic area- or platform-specific.
We are open to a wide variety of collaborations and partnerships along and within our entire value chain – research, manufacturing and development through to commercialisation. If you would like to know more, please contact us at firstname.lastname@example.org.
The Molecular Biotechnology Center (MBC) at the University of Torino, active since September 2006, has the main objective to bring together investigators with different scientific backgrounds to facilitate an interdisciplinary approach to biomedical research.
The Center is actively involved in biotechnological research in the field of biomedical sciences, with specific focus on the study of the molecular mechanisms at the basis of physiopathological processes that have a great impact on human health, such as cardiovascular diseases, inflammation, cancer and stem cell biology.
These research efforts are mainly based on the development of the most advanced molecular imaging technology, bioinformatic analysis and the generation of mouse and zebrafish models. For more information, visit www.mbc.unito.it/en.
Fresenius Medical Care is the world’s leading provider of products and services for people with chronic kidney failure. Around 3.5 million patients worldwide with this disease regularly undergo dialysis treatment. Dialysis is a life-saving blood cleansing procedure that substitutes the function of the kidney in case of kidney failure.
We care for more than 347,000 patients in our global network of more than 4,000 dialysis clinics. At the same time, we operate 45 production sites in more than 20 countries, to provide dialysis products such as dialysis machines, dialyzers and related disposables.
FMC aims to further consolidate its expertise and to use this competence as a basis for sustainable, profitable growth. We aim to continuously improve our patients’ quality of life by offering them high-quality products as well as innovative technologies and treatment concepts.
Fresenius Medical Care’s corporate headquarters is in Bad Homburg v. d. Höhe, Germany. The headquarters in North America is in Waltham, Massachusetts, the headquarters of Asia-Pacific is located in Hongkong and the headquarters of Latin America is in Rio de Janeiro.
Since its foundation in 1889, the Medical Center Hamburg-Eppendorf (UKE) has been one of the leading clinics in Europe.
Based on the interconnection of medicine, research, and teaching, all employees at the UKE work hand in hand toward a common aim – the health and well-being of patients.
With about 13,600 employees, the UKE is the third-largest employer in the Free and Hanseatic City of Hamburg.